What JPM 2026 Told Us About GLP‑1s, Oncology and the New Rules of Engagement
Pharma marketing has finally crossed a line — into consumer territory.
That shift was unmistakable at JPM 2026. Not because science has slowed, but because the way medicines reach people, and the expectations placed on brands, have fundamentally changed.
Nowhere is this more visible than with GLP‑1s.
GLP‑1s: Where Consumer and Clinical Worlds Collide
Weight management, obesity and cardiometabolic health have moved from specialist conversations into everyday culture. GLP‑1s are discussed openly by Patients, covered extensively in mainstream media, and increasingly accessed through direct‑to‑consumer platforms, digital prescribing and integrated delivery models.
This is not just a commercial success story. It is a signal.
GLP‑1s have set a new benchmark for what Patients expect:
- Clear, accessible information
- Frictionless digital journeys
- Transparency on benefits, trade‑offs and outcomes
In short, Patients are behaving like consumers — and they are comparing Pharma experiences to the best digital experiences they have elsewhere.
GLP‑1s Are the Signal, Not the Exception
What stood out at JPM 2026 is that this consumer shift is not limited to one therapy area.
Across the conference, the same dynamics were evident in:
- Oncology, where Patients arrive informed, opinionated and engaged in shared decision‑making
- Rare disease, where online communities and advocacy groups shape awareness faster than traditional campaigns
- CNS and women’s health, where lived experience increasingly drives diagnosis, adherence and trust
- Immunology and inflammation, where long‑term treatment places brand experience alongside clinical efficacy
The implication is clear: Pharma is now competing in the same attention economy as FMCG brands — but under far stricter rules.
The Margin for Error Is Zero
Unlike FMCG, Pharma does not have the luxury of creative experimentation without consequence.
Claims must be accurate. Balance is non‑negotiable. Trust, once lost, is extremely hard to regain.
At the same time, regulators are sharpening guidance around the use of AI and large language models, as these technologies move rapidly from pilots into scaled commercial use. AI is no longer optional – but it must be deployed responsibly, transparently and with human oversight.
Marketing Excellence Now Means Marketing Intelligence
In this environment, marketing excellence is not about producing more content. It is about making better decisions.
The same disciplines that define best‑in‑class FMCG marketing now matter just as much in pharma:
- A deep understanding of which messages resonate — and which don’t
- Rapid feedback loops from real‑world audiences
- Evidence‑led optimization rather than intuition
- Consistency across channels, formats and moments that matter
Messaging can no longer be treated as a creative afterthought. It is a measurable asset — one that directly influences trust, uptake and long‑term brand performance.
What Will Separate Winners in 2026
The winners in 2026 will not simply be those with the most innovative science.
They will be the brands that:
- Listen more closely to patients and healthcare professionals
- Adapt faster to real‑world signals
- Apply intelligence to messaging with the same rigour applied to clinical development
From GLP‑1s to oncology and beyond, we are entering a consumer‑led era of Pharma.
In that world, marketing intelligence is not optional. It is the foundation of trust, performance and sustainable growth.
